Plasma adiponectin levels and five-year survival after first-ever ischemic stroke

Stroke. 2005 Sep;36(9):1915-9. doi: 10.1161/01.STR.0000177874.29849.f0. Epub 2005 Aug 18.

Abstract

Background and purpose: This study aimed to investigate the association between plasma adiponectin levels and 5-year survival after first-ever ischemic stroke.

Methods: Plasma adiponectin measured within 24 hours after first-ever ischemic stroke was related to 5-year outcome. The Kaplan-Meier technique was applied in survival analysis, and the Cox proportional hazards model was used to evaluate the relationship between risk factors and prognosis.

Results: The probabilities of death were 92.8%, 52.5%, and 10.5% (P<0.001) for patients stratified according to tertiles of adiponectin (<4 microg/mL, 4 to 7 microg/mL, and >7 microg/mL, respectively). The relative risk of death was 8.1 (95% CI, 3.1, 24.5; P<0.001) for individuals with adiponectin levels in the lowest tertile compared with the upper tertile. Adiponectin <4 microg/mL (hazard ratio [HR], 5.2; 95% CI, 2.1, 18.4; P<0.001), score >15 in the National Institutes of Health Stroke Scale (HR, 3.6; 95% CI, 1.7, 15.9; P<0.001), and coronary heart disease (HR, 2.9; 95% CI, 1.5, 12.3; P<0.001) were independently associated with mortality.

Conclusions: Low plasma adiponectin is related to an increased risk of 5-year mortality after first-ever ischemic stroke, independently of other adverse predictors.

MeSH terms

  • Adiponectin / blood*
  • Adiponectin / physiology*
  • Aged
  • Brain Ischemia / blood*
  • Brain Ischemia / mortality
  • Brain Ischemia / therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammation
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Prognosis
  • Proportional Hazards Models
  • Risk
  • Risk Factors
  • Stroke / blood*
  • Stroke / mortality
  • Stroke / therapy
  • Time Factors
  • Treatment Outcome
  • Vascular Diseases / therapy

Substances

  • Adiponectin